- English (USA)
- English (UK)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Português (Portugal)
- Polski
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Gentian Diagnostics AS (GENT)
Gentian Diagnostics AS stock price live, this page displays OL GENT stock exchange data. View the GENT premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the Gentian Diagnostics AS real time stock price chart below.
What Is the Gentian Diagnostics AS Stock Price Today?
The Gentian Diagnostics AS stock price today is 55.60.
What Is the Stock Symbol for Gentian Diagnostics AS?
The stock symbol for Gentian Diagnostics AS is "GENT."
What Stock Exchange Does Gentian Diagnostics AS Trade On?
Gentian Diagnostics AS is listed and trades on the Oslo stock exchange.
Is Gentian Diagnostics AS a Good Stock to Buy?
Determining whether Gentian Diagnostics AS—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the GENT quote. (ISIN: NO0010748866)
What Is the Gentian Diagnostics AS Stock Price Today?
The Gentian Diagnostics AS stock price today is 55.60.
What Is the Stock Symbol for Gentian Diagnostics AS?
The stock symbol for Gentian Diagnostics AS is "GENT."
What Stock Exchange Does Gentian Diagnostics AS Trade On?
Gentian Diagnostics AS is listed and trades on the Oslo stock exchange.
Is Gentian Diagnostics AS a Good Stock to Buy?
Determining whether Gentian Diagnostics AS—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the GENT quote. (ISIN: NO0010748866)
55.60
-1.40(-2.46%)
Real-time Data·
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
55.20
57.00
52 wk Range
36.60
61.80
GENT Scorecard
Full Analysis
Holds more cash than debt on its balance sheet
GENT is not included in our AI-picked strategies. See which stocks are.
Review Strategies
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
55.2057.00
52 wk Range
36.6061.80
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
(0.70%)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
(0.70%)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
GENT Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Buy
Analysts Sentiment
Strong Buy
Price Target
67.00
Upside
+20.50%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Net income is expected to drop this year
Gentian Diagnostics Company Profile
Gentian Diagnostics ASA develops, manufactures, and sells biochemical reagents for use in medical diagnostics and research in the United States, Asia, and Europe. The company offers in-vitro diagnostic reagents for clinical chemistry analyzers, such as Gentian Circulating Calprotectin Immunoassay, a turbidimetric assay used for the measurement of calprotectin in plasma and serum for detection and assessment of inflammation; Gentian Cystatin C Immunoassay test kit, a GFR marker for the diagnosis and therapeutic control of renal function and chronic kidney disease; Gentian Retinol-Binding Protein Immunoassay for detection of retinol-binding protein in human serum and plasma; and Canine CRP Immunoassay test kit, a particle-enhanced turbidimetric immunoassay for quantitative determination of canine C-reactive protein in dog plasma and serum. It also develops NT-proBNP Immunoassay, an aid in the diagnosis, monitoring, and assessment of severity in individuals suspected of having congestive heart failure, which is in product development phase. In addition, the company provides faecal calprotectin immunoassay turbo that offers results of calprotectin concentration in stool supporting diagnosis of inflammatory bowel disease; and faecal pancreatic elastase immunoassay turbo, which allows analysis of pancreatic elastase in stool to aid in diagnosis of pancreatic exocrine insufficiency. Gentian Diagnostics ASA was founded in 2001 and is headquartered in Moss, Norway.
Gentian Diagnostics AS Earnings Call Summary for Q1/2025
- Q1 2025 revenue up 16% YoY to NOK 44.5M; EBITDA tripled to NOK 14M; gross margin at 64%
- Cystatin C sales strong at NOK 17.7M; 19 new customers added in U.S. and Asia
- Stock price surged 9.76% post-earnings; company targets 20% annual growth
- NT proBNP product launch planned for 2026; R&D focus maintained despite profitability
- Challenges: wage growth, slower NT proBNP ramp-up, uncertainties in Chinese market
Last Updated: 07-05-2025, 02:28 pm
Read Full TranscriptCompare GENT to Peers and Sector
Metrics to compare | GENT | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipGENTPeersSector | |
|---|---|---|---|---|
P/E Ratio | 17.5x | 30.9x | −0.5x | |
PEG Ratio | 0.02 | 0.03 | 0.00 | |
Price/Book | 4.2x | 3.3x | 2.6x | |
Price / LTM Sales | 5.4x | 3.3x | 3.0x | |
Upside (Analyst Target) | 17.5% | 2.1% | 54.7% | |
Fair Value Upside | Unlock | 3.5% | 8.4% | Unlock |
Analyst Ratings
1 Buy
0 Hold
0 Sell
Ratings:
1 analysts
Overall Consensus
Strong Buy
Analysts 12-Month Price Target:
Average 67.00
(+20.50% Upside)
Earnings
Latest Release
May 08, 2025
EPS / Forecast
-- / --
Revenue / Forecast
-- / --
FAQ
What Is the Gentian Diagnostics (GENT) Stock Price Today?
The Gentian Diagnostics stock price today is 55.60.
What Stock Exchange Does Gentian Diagnostics Trade On?
Gentian Diagnostics is listed and trades on the Oslo Stock Exchange stock exchange.
What Is the Stock Symbol for Gentian Diagnostics?
The stock symbol for Gentian Diagnostics is "GENT."
Does Gentian Diagnostics Pay Dividends? What’s The Current Dividend Yield?
The Gentian Diagnostics dividend yield is 0.7%.
What Is the Gentian Diagnostics Market Cap?
As of today, Gentian Diagnostics market cap is 857.48M.
What Is Gentian Diagnostics's Earnings Per Share (TTM)?
The Gentian Diagnostics EPS (TTM) is 3.17.
When Is the Next Gentian Diagnostics Earnings Date?
Gentian Diagnostics will release its next earnings report on 09 Jul 2025.
From a Technical Analysis Perspective, Is GENT a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2025 - Fusion Media Limited. All Rights Reserved.